Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Getting ready for real-world use of electronic patient-reported outcomes (ePROs) for patients with cancer: A National Comprehensive Cancer Network ePRO Workgroup paper.
Cracchiolo JR, Arafat W, Atreja A, Bruckner L, Emamekhoo H, Heinrichs T, Raldow AC, Smerage J, Stetson P, Sugalski J, Tevaarwerk AJ. Cracchiolo JR, et al. Among authors: tevaarwerk aj. Cancer. 2023 Aug 15;129(16):2441-2449. doi: 10.1002/cncr.34844. Epub 2023 May 24. Cancer. 2023. PMID: 37224181 No abstract available.
Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.
Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, Martino S, Ingle JN, Sparano JA, Solin LJ, Wood WC, Robert NJ. Tevaarwerk AJ, et al. J Clin Oncol. 2014 Dec 10;32(35):3948-58. doi: 10.1200/JCO.2014.55.6993. Epub 2014 Oct 27. J Clin Oncol. 2014. PMID: 25349302 Free PMC article. Clinical Trial.
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G. LoConte NK, et al. Invest New Drugs. 2015 Feb;33(1):169-76. doi: 10.1007/s10637-014-0166-6. Epub 2014 Oct 17. Invest New Drugs. 2015. PMID: 25318436 Free PMC article. Clinical Trial.
Survivor and Clinician Assessment of Survivorship Care Plans for Hematopoietic Stem Cell Transplantation Patients: An Engineering, Primary Care, and Oncology Collaborative for Survivorship Health.
Morken CM, Tevaarwerk AJ, Swiecichowski AK, Haine JE, Williams ZT, Norslien K, Arroyo N, Zhang X, Campbell B, Mendonca EA, Juckett MB, Sesto ME. Morken CM, et al. Among authors: tevaarwerk aj. Biol Blood Marrow Transplant. 2019 Jun;25(6):1240-1246. doi: 10.1016/j.bbmt.2019.02.003. Epub 2019 Feb 11. Biol Blood Marrow Transplant. 2019. PMID: 30763727 Free PMC article.
Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Kvale E, Lally RM, Langbaum TS, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, Freedman-Cass DA, McMillian NR. Denlinger CS, et al. J Natl Compr Canc Netw. 2017 Sep;15(9):1140-1163. doi: 10.6004/jnccn.2017.0146. J Natl Compr Canc Netw. 2017. PMID: 28874599 Free PMC article.
In the interest of full disclosure.
Burkard ME, Tevaarwerk AJ, Wisinski KB. Burkard ME, et al. Among authors: tevaarwerk aj. Lancet Oncol. 2010 Apr;11(4):314-5; author reply 315. doi: 10.1016/S1470-2045(10)70044-9. Lancet Oncol. 2010. PMID: 20359661 No abstract available.
101 results